Zomedica Pharmaceuticals Corp. Common Shares (ZOM): Price and Financial Metrics


Zomedica Pharmaceuticals Corp. Common Shares (ZOM)

Today's Latest Price: $0.19 USD

0.01 (5.47%)

Updated Dec 2 4:00pm

Add ZOM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ZOM Stock Price Chart Interactive Chart >

Price chart for ZOM

ZOM Price/Volume Stats

Current price $0.19 52-week high $0.50
Prev. close $0.18 52-week low $0.06
Day low $0.17 Volume 117,277,794
Day high $0.20 Avg. volume 36,166,273
50-day MA $0.10 Dividend yield N/A
200-day MA $0.16 Market Cap 106.55M

Zomedica Pharmaceuticals Corp. Common Shares (ZOM) Company Bio


Zomedica Pharmaceuticals Corp. operates as a veterinary pharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of drugs, novel drug delivery systems, devices, and diagnostics for the health and wellness of companion animals, such as canine, feline, and equine. The company has a research collaboration agreement with Celsee Diagnostics, Inc. to test the feasibility of Celsee's liquid biopsy technology for veterinary application as a canine cancer diagnostics. Zomedica Pharmaceuticals Corp. was founded in 2015 and is based in Ann Arbor, Michigan.


ZOM Latest News Stream


Event/Time News Detail
Loading, please wait...

ZOM Latest Social Stream


Loading social stream, please wait...

View Full ZOM Social Stream

Latest ZOM News From Around the Web

Below are the latest news stories about Zomedica Pharmaceuticals Corp that investors may wish to consider to help them evaluate ZOM as an investment opportunity.

Zomedica Pharma reverse stock split proposal didn't receive shareholders majority

Zomedica Pharmaceuticals ([[ZOM]] +12.3%) announces that its proposal for share consolidation/reverse stock split did not receive the two-thirds majority vote at its shareholders meeting.The company also amended article for a change in name to "Zomedica Corp." from "Zomedica Pharmaceuticals Corp."Previously: Zomedica to develop gastrointestinal testing panel for Truforma (Sept. 8)...

Seeking Alpha | September 25, 2020

Zomedica Announces Second Quarter 2020 Financial Results

ANN ARBOR, Mich., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (“Zomedica” or “Company”), a veterinary health…

GlobeNewswire | August 10, 2020

Zomedica Pharmaceuticals Corp. (ZOM) Gains But Lags Market: What You Should Know

Zomedica Pharmaceuticals Corp. (ZOM) closed the most recent trading day at $0.16, moving +0.57% from the previous trading session.

Yahoo Finance | August 3, 2020

28 Stocks Moving in Wednesday's Pre-Market Session

Gainers Mexco Energy Corporation (NYSE: MXC ) shares rose 201.7% to $10.50 in pre-market trading after jumping over 18% on Tuesday. TransAtlantic Petroleum Ltd. (NYSE: TAT ) rose 123.5% to $0.7005 in pre-market trading following a 23% surge in the previous session. Oblong Inc. (NYSE: OBLG ) rose 53% to $3.78 in pre-market trading after declining 12% on Tuesday. U.S. Energy Corp. (NASDAQ: USEG ) shares rose 43% to $7.16 in pre-market trading after gaining around 6% on Tuesday. Barnwell Industries, Inc. (NYSE: BRN ) rose 41.5% to $1.38 in pre-market trading after surging around 10% on Tuesday. Atossa Therapeutics, Inc. (NASDAQ: ATOS ) rose 25.7% to $4.65 in pre-market trading. Avance Clinical has been contracted for Atossa Therapeutics’ AT-301 nasal spray clinical study. Intec Pharma Ltd....

Benzinga Feeds | July 22, 2020

Successful Remote Installation of TRUFORMA™

ANN ARBOR, Mich., July 21, 2020 -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary health company, announced today that, in.

Yahoo | July 21, 2020

Read More 'ZOM' Stories Here

ZOM Price Returns

1-mo 183.58%
3-mo 55.87%
6-mo 8.57%
1-year -38.53%
3-year -91.48%
5-year N/A
YTD -42.60%
2019 -73.09%
2018 -37.88%
2017 91.99%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.812 seconds.